Nomogram for Predicting Efficacy and Prognosis After Chemotherapy for Advanced NSCLC

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2024 Aug 9

PMID 39118382

Authors

Jiaying Gao

Yandong Nan

Gang Liu

Shihong Zhao

Huanqing Xiong

Yifeng Wang

Faguang Jin

Affiliations

Soon will be listed here.

Abstract

Purpose: One major issue is the therapeutic effect following chemotherapy for non-small cell lung cancer (NSCLC). Although numerous risk factors have been identified and novel therapies have been developed, improving patient overall survival (OS) remains a crucial postoperative issue. This study aimed to develop a nomogram for accurately predicting the OS of patients with Stage III-IV NSCLC treated with chemotherapy.

Methods: The Department of Respiration at Tangdu Hospital, Air Force Medical University, prospectively collected data on 321 patients between January 2018 and December 2023. A week before treatment, the platelet-to-lymphocyte ratio (PLR), the neutrophil-to-lymphocyte ratio (NLR), and seven autoantibodies were measured using Youden's index, which was obtained using the ROC curve. The formula was used to compute the values of PLR and NLR. After using multifactor Cox regression analysis to identify risk factors, a nomogram was produced regarding the therapeutic effect following chemotherapy. The performance of the nomogram was assessed using a bootstrapped-concordance index and calibration plots.

Result: It was determined that NLR, sex-determining region Y-box 2 (SOX2), adenosine triphosphate binding RNA deconjugase 4-5 (GBU4-5), and MAGE family member A1 (MAGEA1) were significantly associated factors that could be combined to accurately predict the therapeutic effect following chemotherapy. Utilizing these risk indicators, we were able to develop a nomogram that predicted the patients' survival at 1, 3, and 5 years. At 3 years, the area under the curve representing the expected survival probability was 0.762 (95% confidence interval 0.66-0.87). With a bootstrapped-concordance index of 0.762, the nomogram demonstrated good calibration.

Conclusions: Our nomogram proved to be a valuable instrument in accurately predicting the overall survival of patients.

Citing Articles

A prognostic nomogram of non-small cell lung cancer based on tumor marker inflammatory nutrition score.

Feng Y, Qiao H, Han X, Tang H Transl Lung Cancer Res. 2025; 13(12):3392-3406.

PMID: 39830779 PMC: 11736597. DOI: 10.21037/tlcr-24-708.

References

Vieler M, Sanyal S . p53 Isoforms and Their Implications in Cancer. Cancers (Basel). 2018; 10(9). PMC: 6162399. DOI: 10.3390/cancers10090288. View

Ren S, Zhang S, Jiang T, He Y, Ma Z, Cai H . Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology. 2018; 7(2):e1384108. PMC: 5749655. DOI: 10.1080/2162402X.2017.1384108. View

Alsaab H, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw S . PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017; 8:561. PMC: 5572324. DOI: 10.3389/fphar.2017.00561. View

Litiere S, Collette S, de Vries E, Seymour L, Bogaerts J . RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2016; 14(3):187-192. DOI: 10.1038/nrclinonc.2016.195. View

Trudgen K, Khattar N, Bensadoun E, Arnold S, Stromberg A, Hirschowitz E . Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts. PLoS One. 2014; 9(2):e87947. PMC: 3912196. DOI: 10.1371/journal.pone.0087947. View

Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, Ciccone L . Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial. Cancers (Basel). 2022; 14(24). PMC: 9776592. DOI: 10.3390/cancers14246074. View

Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J . Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. J Thorac Oncol. 2019; 14(12):2071-2083. DOI: 10.1016/j.jtho.2019.08.008. View

Qu Z, Wang Q, Wang H, Jiao Y, Li M, Wei W . The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy. Front Oncol. 2022; 12:783197. PMC: 8845037. DOI: 10.3389/fonc.2022.783197. View

Haemmerle M, Stone R, Menter D, Afshar-Kharghan V, Sood A . The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018; 33(6):965-983. PMC: 5997503. DOI: 10.1016/j.ccell.2018.03.002. View

10.

Schooten E, Di Maggio A, Van Bergen en Henegouwen P, Kijanka M . MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev. 2018; 67:54-62. DOI: 10.1016/j.ctrv.2018.04.009. View

11.

Hess D . A nomogram for use of non-invasive respiratory strategies in COVID-19. Lancet Digit Health. 2021; 3(3):e140-e141. PMC: 7906639. DOI: 10.1016/S2589-7500(21)00006-6. View

12.

Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C . Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015; 210(3):526-35. DOI: 10.1016/j.amjsurg.2015.03.022. View

13.

Fang X, Yoon J, Li L, Tsai Y, Zheng S, Hood L . Landscape of the SOX2 protein-protein interactome. Proteomics. 2011; 11(5):921-34. DOI: 10.1002/pmic.201000419. View

14.

Liu C, Zhao W, Xie J, Lin H, Hu X, Li C . Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. Front Immunol. 2023; 14:1115291. PMC: 9978193. DOI: 10.3389/fimmu.2023.1115291. View

15.

Pascual-Figal D, Bayes-Genis A, Asensio-Lopez M, Hernandez-Vicente A, Garrido-Bravo I, Pastor-Perez F . The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. J Am Coll Cardiol. 2019; 73(9):1016-1025. DOI: 10.1016/j.jacc.2018.11.054. View

16.

Leonetti A, Wever B, Mazzaschi G, Assaraf Y, Rolfo C, Quaini F . Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019; 46:100644. DOI: 10.1016/j.drup.2019.100644. View

17.

Boyle P, Chapman C, Holdenrieder S, Murray A, Robertson C, Wood W . Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 22(2):383-9. PMC: 3030465. DOI: 10.1093/annonc/mdq361. View

18.

Zhang J, Tan E . Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010; 10(3):321-8. PMC: 2896686. DOI: 10.1586/erm.10.12. View

19.

Wu J, Zhang H, Li L, Hu M, Chen L, Xu B . A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. Cancer Commun (Lond). 2020; 40(7):301-312. PMC: 7365459. DOI: 10.1002/cac2.12067. View

20.

Holdenrieder S . Biomarkers along the continuum of care in lung cancer. Scand J Clin Lab Invest Suppl. 2016; 245:S40-5. DOI: 10.1080/00365513.2016.1208446. View